TickerGuard
Buy Day today: Neutral (57) Mixed market breadth · no major macro event
REGN

Regeneron Pharmaceuticals Inc

Healthcare · Biotechnology

746.50$ +0.9% vs. previous close Closing price · As of: Oct 9, 2026

Statements

Cash Flow

Regeneron Pharmaceuticals Inc (REGN) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at 575 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Cash Flow REGN
Line item Q3 16 Q4 16 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19 Q4 19 Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 LTM
651 378 356 -31 415 567 619 395 453 729 897 188 557 787 698 943 -254 1,231 669 627 3,414 2,373 2,102 564 629 1,720 1,368 1,022 1,114 1,090 1,513 354 1,291 1,263 1,045 1,144 1,619 1,171 1,079 575 4,443
28 29 38 35 38 35 36 34 35 43 51 52 53 54 56 59 59 62 67 71 73 75 74 74 93 100 100 103 105 113 114 121 122 126 127 135 137 145 123 124 529
131 155 134 121 125 127 82 107 111 127 108 106 117 134 106 104 101 122 131 146 137 188 167 160 166 232 239 202 204 240 230 223 225 304 256 252 237 249 257 243 987
386 125 107 -418 27 393 141 -157 -142 -92 436 -4.8 -112 -4.6 73 46 -1,096 82 -447 -58 1,781 144 1,128 -288 -687 523 550 54 – – – – – – – – – – – – –
249 80 -28 -592 -92 -215 33 -237 -243 -249 312 -183 -300 -29 -181 34 -1,321 -35 -539 -2,485 1,463 -355 823 -781 -667 382 241 -81 -192 -61 441 -909 468 -86 130 -228 625 5.9 -77 -161 392
119 150 50 55 60 108 79 112 106 86 74 95 122 139 170 130 153 161 115 149 133 155 142 154 143 152 178 113 176 314 162 211 184 267 272 177 201 249 231 240 921
-406 -271 -140 -170 -359 -336 -425 -485 -287 -266 -776 -836 -207 -209 -443 1,453 -776 -305 -1,059 126 -2,439 -2,013 -1,705 -414 192 -1,858 -236 -2,387 -496 -66 -1,687 -557 -574 351 648 -1,094 -403 220 -429 -93 -704
5.2 308 0.0 0.0 0.0 244 0.0 0.0 0.0 – – – – – – – – 681 – – – – – – – – – – – – 0.0 0.0 – – 94 93 91 93 98 97 379
-1.9 -96 17 -31 -46 -224 13 -32 -50 -110 -21 -30 -19 -394 -476 -5,469 -173 -409 -461 -331 -436 -1,449 -457 -408 -1,044 -620 -808 -705 -676 -747 -291 -604 -735 -973 -1,046 -1,062 -664 -672 -794 -1,169 -3,299
4.4 -31 44 -7.1 – 37 – – – – – – 1,500 1,500 1,500 1,500 482 – – – – – – – – – – – – – – – – – – – – – – – –
29 -492 61 134 -8.2 -211 13 -11 3.7 -83 120 -15 -11 -346 336 -2,613 612 -305 -366 -118 385 -907 65 -101 -725 -248 -323 -614 -407 -446 47 -478 -634 -1,136 -1,089 -1,128 -718 -780 -802 -2,345 -4,645
274 -385 277 -67 48 21 207 -102 170 380 241 -663 339 233 590 -216 -418 621 -757 634 1,360 -547 461 49 96 -385 809 -1,979 211 578 -128 -682 84 477 604 -1,077 498 611 -153 -1,863 -908
532 227 305 -85 355 459 539 283 347 643 823 94 436 648 528 814 -408 1,070 553 478 3,280 2,218 1,960 411 486 1,568 1,189 909 938 776 1,351 143 1,108 996 774 968 1,417 922 848 334 3,522

LTM = last twelve months (sum of the four most recent quarters).

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?